This week we begin a new Homerun Slides series covering Hypo and Hyperglycemia from our Editor-in-chief, Dave Joffe, BSPharm, CDE, FACA, which will include facts and figures on this burgeoning epidemic.

When it comes to weight loss medications the FDA’s motto appears to be, “If at first you don’t get approval, try, try, again,” and it worked as an FDA advisory panel recommended the approval of Qnexa after two previous rejections (See this week’s Item #3). This might just open the …

Insulution Introduces the Daily Dose(TM) The World’s Smallest Syringe: Daily Dose is the world’s smallest insulin syringe and is designed to satisfy the requirement to be small, neat and convenient. Daily Dose is easily carried, for example, in a wallet or the cash pocket of jeans, so patients will have …

A recent study found that the rates of diabetic polyneuropathy are similar in people with prediabetes and healthy people. This finding suggests that prediabetes may not be to blame for many cases of nerve damage and does not directly cause higher rates of diabetic neuropathies, even though the condition precedes …

The study found women who spend the most time sitting down during the week are more likely to show early signs of type 2 diabetes than those who are more active. Blood tests revealed they had higher levels of markers that suggest the body is well on the way to …

Dieters have the option of many weight-loss plans and programs, but too much information can become paralyzing, nutrition experts say. They add that all plans can get results if people stick to them and are accountable. Gary Foster of Temple University’s Center for Obesity Research and Education simplifies it by …

Thirty-five percent of the time for 250,000 newly diagnosed diabetes patients, physicians did not follow the ADA/EASD consensus guidelines for recommended treatment.…

The high cost of diagnosing peripheral neuropathy could be greatly reduced if doctors ordered the right tests.…

The FDA Endocrinologic and Metabolic Drugs Advisory Committee voted overwhelmingly (20 to 2) in favor of approving the obesity drug Qnexa (Vivus, Inc.), a combination of phentermine and controlled-release topiramate. Qnexa could be the first prescription drug for obesity to reach the market since 1999.…

An FDA advisory committee’s endorsement of the anti-obesity drug Qnexa could re-energize the pharmaceutical industry after several years of disappointment in trying to develop anti-obesity drugs.…